Mirum's LIVMARLI Now Authorized In Canada For Cholestatic Pruritus In Patients With Alagille Syndrome
Portfolio Pulse from Happy Mohamed
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has received authorization from Health Canada for its medication LIVMARLI® (maralixibat oral solution) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). This approval is supported by over six years of LIVMARLI data showing improvements in pruritus and serum bile acids. LIVMARLI is also approved in the United States and Europe for the same indication. Mirum has submitted a supplemental new drug application to the FDA and EMA for approval of LIVMARLI in cholestatic pruritus associated with progressive familial intrahepatic cholestasis (PFIC).
July 25, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirum Pharmaceuticals' LIVMARLI has been authorized by Health Canada, expanding its market reach. This could potentially boost the company's revenues and profitability in the short term.
The approval of LIVMARLI in Canada expands the market for Mirum Pharmaceuticals, potentially leading to increased sales and revenues. This news is highly relevant as it directly pertains to the company's product and its market reach. The importance is high as regulatory approvals can significantly impact a pharmaceutical company's performance. The confidence in this analysis is high based on the direct relationship between product approvals and company performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100